Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Prospective, Open-Label, Multicenter Randomized Phase III Trial to Compare The Efficacy and Safety of A Combined Regimen of Obinutuzumab and Venetoclax Versus Obinutuzumab and Chlorambucil in Previously Untreated Patients With CLL and Coexisting Medical Conditions
Brief Summary: This open-label, multicenter, randomized Phase III study is designed to compare the efficacy and safety of a combined regimen of obinutuzumab and venetoclax versus obinutuzumab + chlorambucil in participants with chronic lymphocytic leukemia (CLL) and coexisting medical conditions. The time on study treatment was approximately one year and the follow-up period will be up to 9 years


Options:
A: Arm Label: Safety Run-in Obinutuzumab + Venetoclax; Type: EXPERIMENTAL; Interventions: Drug: Venetoclax, Drug: Obinutuzumab | Arm Label: Obinutuzumab + Chlorambucil; Type: EXPERIMENTAL; Interventions: Drug: Chlorambucil, Drug: Obinutuzumab | Arm Label: Obinutuzumab + Venetoclax; Type: EXPERIMENTAL; Interventions: Drug: Venetoclax, Drug: Obinutuzumab | Intervention Type: DRUG; Name: Chlorambucil; Assigned to Arm(s): Obinutuzumab + Chlorambucil | Intervention Type: DRUG; Name: Venetoclax; Assigned to Arm(s): Obinutuzumab + Venetoclax, Safety Run-in Obinutuzumab + Venetoclax | Intervention Type: DRUG; Name: Obinutuzumab; Assigned to Arm(s): Obinutuzumab + Chlorambucil, Obinutuzumab + Venetoclax, Safety Run-in Obinutuzumab + Venetoclax
B: Arm Label: Treatment Arm A: Ibrutinib and Venetoclax (I+VEN); Type: EXPERIMENTAL; Interventions: Drug: Ibrutinib, Drug: Venetoclax, Drug: Ibrutinib (as Subsequent Therapy) | Arm Label: Treatment Arm B: Chlorambucil and Obinutuzumab (G-Clb); Type: ACTIVE_COMPARATOR; Interventions: Drug: Chlorambucil, Drug: Obinutuzumab, Drug: Ibrutinib (as Subsequent Therapy) | Intervention Type: DRUG; Name: Ibrutinib; Assigned to Arm(s): Treatment Arm A: Ibrutinib and Venetoclax (I+VEN) | Intervention Type: DRUG; Name: Venetoclax; Assigned to Arm(s): Treatment Arm A: Ibrutinib and Venetoclax (I+VEN) | Intervention Type: DRUG; Name: Chlorambucil; Assigned to Arm(s): Treatment Arm B: Chlorambucil and Obinutuzumab (G-Clb) | Intervention Type: DRUG; Name: Obinutuzumab; Assigned to Arm(s): Treatment Arm B: Chlorambucil and Obinutuzumab (G-Clb) | Intervention Type: DRUG; Name: Ibrutinib (as Subsequent Therapy); Assigned to Arm(s): Treatment Arm A: Ibrutinib and Venetoclax (I+VEN), Treatment Arm B: Chlorambucil and Obinutuzumab (G-Clb)
C: Arm Label: Cohort 1: Bendamustine + Rituximab; Type: EXPERIMENTAL; Interventions: Drug: Bendamustine, Drug: Rituximab | Arm Label: Cohort 1: Zanubrutinib; Type: EXPERIMENTAL; Interventions: Drug: Zanubrutinib | Arm Label: Cohort 1a (China only): Bendamustine + Rituximab; Type: EXPERIMENTAL; Interventions: Drug: Bendamustine, Drug: Rituximab | Arm Label: Cohort 1a (China only): Zanubrutinib; Type: EXPERIMENTAL; Interventions: Drug: Zanubrutinib | Arm Label: Cohort 2: Zanubrutinib; Type: EXPERIMENTAL; Interventions: Drug: Zanubrutinib | Arm Label: Cohort 3: Venetoclax + Zanubrutinib; Type: EXPERIMENTAL; Interventions: Drug: Zanubrutinib, Drug: Venetoclax | Intervention Type: DRUG; Name: Zanubrutinib; Assigned to Arm(s): Cohort 1: Zanubrutinib, Cohort 1a (China only): Zanubrutinib, Cohort 2: Zanubrutinib, Cohort 3: Venetoclax + Zanubrutinib | Intervention Type: DRUG; Name: Bendamustine; Assigned to Arm(s): Cohort 1: Bendamustine + Rituximab, Cohort 1a (China only): Bendamustine + Rituximab | Intervention Type: DRUG; Name: Rituximab; Assigned to Arm(s): Cohort 1: Bendamustine + Rituximab, Cohort 1a (China only): Bendamustine + Rituximab | Intervention Type: DRUG; Name: Venetoclax; Assigned to Arm(s): Cohort 3: Venetoclax + Zanubrutinib
D: Arm Label: IBR + OB; Type: EXPERIMENTAL; Interventions: Drug: Ibrutinib, Drug: Obinutuzumab | Arm Label: CLB + OB; Type: EXPERIMENTAL; Interventions: Drug: Obinutuzumab, Drug: Chlorambucil | Intervention Type: DRUG; Name: Ibrutinib; Assigned to Arm(s): IBR + OB | Intervention Type: DRUG; Name: Obinutuzumab; Assigned to Arm(s): CLB + OB, IBR + OB | Intervention Type: DRUG; Name: Chlorambucil; Assigned to Arm(s): CLB + OB

Answer: A